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Brentuximab vedotin (BV), an antibody-drug conjugate that targets CD30, induces high response rates in
CD30þ lymphoid malignancies. It is unknown if BV use affects procurement of autologous CD34þ stem cells
and hematopoietic engraftment after autologous stem cell transplantation (ASCT). We examined 42 patients
treated with BV before mobilization. Median times from diagnosis to transplantation, from initial BV treat-
ment to transplantation, and from last BV treatment to stem cell collection were 21 months (range, 10 to 210),
5 months (range, 1.5 to 16.8), and 30 days (range, 2 to 280), respectively. Mobilization was successful on the
ﬁrst attempt in 38 patients (90.4%). The median number of infused CD34þ cells was 5.46  106/kg (range, 1.65
to 54.78  106/kg). The median times to neutrophil and platelet engraftment were 10 (range, 9 to 13), and
10.5 days (range, 7 to 35), respectively. BV before high-dose chemotherapyeASCT did not adversely affect
peripheral blood stem cell mobilization and subsequent engraftment in a cohort of heavily pretreated pa-
tients with CD30þ lymphomas.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy (HDC) followed by autologous
stem cell transplantation (ASCT) is an established standard
for treatment of relapsed Hodgkin lymphoma (HL) and non-
Hodgkin lymphoma [1]. Successful engraftment depends
largely on the collection of an adequate number of hemato-
poietic progenitor cells (HPCs). Although the optimal dose
for rapid neutrophil and platelet engraftment is considered
to be >5  106 CD34þ cells/kg [2,3], 5% to 40% of patients fail
to collect a minimum of 2  106 CD34þ cells per kilogram
[4-6]. Speciﬁc antineoplastic agents, including lenalidomide
[7,8], ﬂudarabine [9,10], and melphalan [11], have been
associated with poor mobilization rates. Recent studies have
shown that stem cell mobilization is impaired in patients
with diabetes or glucose intolerance [12,13].
The antibody-drug conjugate brentuximab vedotin (BV)
has been shown to result in high response in CD30þ malig-
nancies [14,15]. Phase II studies showed BV results in overall
response rates of 75% in relapsed/refractory HL [16] and 86%
in relapsed refractory anaplastic large cell lymphoma [17].
When used as salvage before reduced-intensity allogeneic
hematopoietic stem cell transplantation, BV did not appear
to adversely affect engraftment, incidence of graft-versus-
host disease, or survival [18]. In a follow-up report, BV wasdgments on page 1531.
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15.04.022associated with improved progression-free survival and
reduced transplantation-related mortality [19].
Initial studies have explored the use of BV in combination
with chemotherapy for ﬁrst line treatment of HL [20] and
CD30þ peripheral T cell lymphomas [21]. Ongoing studies are
investigating the use of BV alone or in combination with
chemotherapy for salvageof CD30þ lymphomas inﬁrst relapse.
It is unknown whether use of BV before hematopoietic
cell mobilization would affect collection of CD34þ stem cells
and subsequent engraftment. We, therefore, examined the
outcomes 42 patients who were treated with BV before
HDC-ASCT.
METHODS
We retrospectively reviewed the HDC-ASCT databases of University
Hospitals Case Medical Center (UHCMC) and MD Anderson Cancer Center.
Forty-two patients who were treated with BV before HDC-ASCT between
February 2009 and April 2014 were included. BV treatment was prescribed
as part of standard of care for HL and anaplastic large cell lymphoma or
within clinical studies including diffuse large B cell lymphoma and other
lymphomas. Clinical data collected included age, gender, histologic diag-
nosis, complete blood count, RBC, platelet transfusion history, time from
diagnosis to transplantation, time from initial BV treatment to trans-
plantation, time from last BV treatment to stem cell collection, history of
prior therapies, and number of mobilization procedures. Chemotherapy/
granulocyte colonyestimulating factor (G-CSF) in ﬁrst mobilization was
standard atMDAnderson Cancer Center, whereas plerixafor/G-CSFwas used
as ﬁrst mobilization regimen at UHCMC. Successful peripheral blood HPC
mobilization was deﬁned as achieving a target of 2  106 CD34þ cells/kg. A
cohort of 125 lymphoma patients who underwent ASCT without prior BV
treatment between 2004 and 2014 at UHCMC was used as a control for
mobilization yield.
Differences between groups were examined with the student t-test.
Correlations were studied with the Pearson product-moment correlation
coefﬁcient. Response was assessed using standard criteria [22]. Overall
survival and actuarial event-free probabilities were calculated by the
Kaplan-Meier method [23].
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Median age was 37 years (range, 18 to 67); 52% (n ¼ 22)
were male (Table 1). Diagnoses were HL (n ¼ 30; 71) and
non-Hodgkin lymphoma (n ¼ 12; 29%; anaplastic large cell,
n ¼ 6; diffuse large B cell, n ¼ 3; unknown subtype, n ¼ 3).
Median times from diagnosis to transplantation, from initial
BV treatment to transplantation, and from last BV treatment
to stem cell collection were 21 months (range, 10 to 210), 5
months (range, 1.5 to 16.8), and 30 days (range, 2 to 280),
respectively. Our subjects had failed multiple conventional
treatments with a median of 3 (range, 2 to 8) lines of
treatment before HDC-ASCT. Fifteen patients (35%) received
prior radiation therapy; radiation ﬁelds included medias-
tinum (n ¼ 7), mantle (n ¼ 3), neck (n ¼ 2), lower extremity
(n ¼ 1), and right acetabulum (n ¼ 1). The site of radiation
was not available for 2 patients. One subject had radiation to
both mantle ﬁeld and right acetabulum. BV was given at 1.8
mg/kg i.v. every 21 days. Median number of BV cycles was 4
(range, 1 to 16).
The overall response rate to BV treatment was 72%
(complete response, 55% and partial response, 17%). Thirty
patients (71%) were in complete remission at the time of
transplantation (second complete remission ¼ 6; 3 com-
plete remission ¼ 24), 4 (10%) were in partial remission
(second partial remission ¼ 1; 3partial remission ¼ 3), 6
patients (14%) had stable disease, and 2 patients (5%) un-
derwent transplantation with progressive disease.
The mobilization regimens included chemotherapy/
G-CSF in 32 patients (76%) and plerixafor/G-CSF in
10 patients (24%). Thirty-eight (90.4%) of 42 patients were
successfully mobilized on the ﬁrst attempt. Three subjects
(7.1%) required a second mobilization regimen for
successful collection. Secondmobilization regimens included
cyclophosphamide/G-CSF (n ¼ 2) and plerixafor/G-CSF (n ¼
1). One patient who proceeded to ASCT after ﬁrst mobiliza-
tion yielded a borderline graft content of 1.65  106 CD34þ
cells/kg.
The median number of infused CD34þ cells for the whole
cohort was 5.46  106/kg (range, 1.65 to 54.78  106/kg).
Because the ﬁrst-line mobilization regimen was different
between centers, we compared the number of CD34þ cells
collected according to mobilization agent. There was no
statistically signiﬁcant difference in the CD34þ cell dose of
patients mobilized with ﬁrst-line plerixafor/G-CSF (median,Table 1
Baseline Characteristics of the Patient Population
Characteristic Value
Age, median (range), yr 37 (18-67)
Diagnosis, n (%)
HL 30 (71)
Non-Hodgkin lymphoma 12 (29)
Anaplastic large cell lymphoma 6 (14)
Diffuse large B cell lymphoma 3 (7)
Other 3 (7)
Number of prior lines of therapy, median 3
Previous radiation therapy, n (%) 15 (35)
Best response to brentuximab, n (%)
CR 23 (55)
PR 7 (17%)
Time from diagnosis to transplantation, median (range),
mo
21 (10-210)
Time from last BV treatment to transplantation, median
(range), mo
5 (1-11)
Time from last BV treatment to HPC collection, median
(range), d
30 (2-280)
CR indicates complete response; PR, partial response.4.81  106/kg) or with chemotherapy and G-CSFebased
regimens (median, 5.53  106/kg) (P ¼ .35).
There was no statistically signiﬁcant correlation between
thenumber of cycles of BV administered and number of CD34þ
cells/kg (P¼ .59). Themedian number of CD34þ cells collected
was 5.5  106/kg and 5.24  106/kg for patients receiving 5 or
more cycles and 4 cycles or less, respectively (P ¼ .45).
We also compared collection results after BV with those
of a cohort of patients who underwent autologous trans-
plantation for relapsed lymphoma and who did not receive
BV (n ¼ 125). There was no difference in the median number
of cells collected with prior BV (mean ¼ 6.9  106/kg;
median ¼ 5.46  106/kg) and without previous BV (mean ¼
5.78 106/kg; median¼ 5.1106/kg), (P¼ .38). Mobilization
yields remained comparable when we excluded patients
who had HPCs collected after plerixafor-containing mobili-
zation regimens (P ¼ .58). Similarly, prior radiation therapy
did not result in lower HPC collection (median CD34þ cell
dose: prior radiation ¼ 5.45  106/kg; no prior radiation ¼
5.72  106/kg; P ¼ .46).
All patients engrafted neutrophils and platelets at a me-
dian time of 10 days (range, 9 to 13) and 10.5 days (range, 7 to
35), respectively. The median time to RBC transfusion inde-
pendence was 8 days (range, 0 to 34). With a median follow-
up of 12 months, day 100 and 1-year treatment-related
mortality rates were 0%. Although patients in our cohort
were heavily pretreated, 1-year actuarial event-free and
overall survival were 52.7% and 81.6%, respectively (Figure 1).DISCUSSION
To our knowledge, a possible effect of BV in the mobili-
zation of HPCs before ASCT has not been examined before. In
this report, we show HPC harvesting is feasible after treat-
ment with BV in patients who receivedmultiple prior lines of
chemotherapy. More than 90% of our patients were
successfully mobilized on the ﬁrst attempt.
Accordingly, hematopoietic engraftment was not affected
by prior BV therapy. Neutrophil and platelet engraftment
times were comparable to those reported after ASCT in
lymphoid malignancies [24].
This report has limitations, particularly its retrospective
nature and the inclusion of a heterogeneous patient popu-
lation. In addition, the majority of patients received a small
number of cycles of BV before mobilization (median of 4
cycles). It is possible that subjects with more prolonged
exposure to this agent may have impaired stem cellFigure 1. Progression-free (solid line) and overall survival (dashed line) after
ASCT of 42 patients treated with brentuximab vedotin before autologous he-
matopoietic cell mobilization.
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correlation between the number of BV cycles and HPC
mobilization yields, and CD34þ cell doses were comparable
to those obtained from patients without exposure to BV.
Furthermore, if BV is used in salvage before ASCT, it is likely
that the goal will be to administer only enough cycles to
achieve remission, a strategy that is represented in our pa-
tient population. Although radiation did not affect HPC
mobilization here, none of our subjects received extensive
radiation to hematopoietic sites. Several trials are investi-
gating the use of BV combined with chemotherapy for the
treatment of lymphoid malignancies, and the effect of these
combinations on stem cell mobilization will need to be
evaluated in future studies.
The early post-transplantation disease control is likely
reﬂective of the high activity of BV against CD30þ lymphoid
malignancies. The only patient who relapsedwithin 100 days
of ASCT had a bulky mediastinal mass and was later treated
with radiation and allogeneic HSCT.
With the advent of new, targeted therapies, it remains
important to demonstrate that they do not represent a hin-
drance to subsequent therapeutic plans. The high rates of
response and excellent tolerability of BV will likely lead to its
use in earlier lines of therapy. Our results would suggest that
BV does not adversely affect HPC mobilization and subse-
quent engraftment.
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